



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Rory F. Finn

Serial No. 10/771,895

Filed: February 4, 2004

)
) Attorney Docket No: PC 32152A

)
) Group Art Unit: 1654

)
) Examiner: Maury A. Audet

For: N-TERMINALLY MONOPEGYLATED HUMAN GROWTH HORMONE
CONJUGATES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE
THEREOF

August 23, 2006

Commissioner for Patents
Alexandria, VA. 22313-1450


SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$630.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,


S. Christopher Bauer, Reg. No. 42,305
Agent for Applicant
(314) 274-6257 (St. Louis)

08/24/2006 MBLANCO 00000002 191025 10771895
02 FC:1806 180.00 DA

Pharmacia Corporation of Pfizer Inc
P. O. Box 1027
Chesterfield, MO 63006

**FORM PTO-1449**U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICEATTY. DOCKET
NO.: PC 32152AAPPLICATION NO.
10/771,895**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

INVENTOR: Rory F. Finn

Filed: February 4, 2004

Group: 1654

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,990,237	11/12/99	Bentley, et al.			
	A2	6,465,694 B1	10/15/02	Baudys, et al.			
	A3	6,495,659 B2	12/17/02	Bentley, et al.			
	A4	5,824,784	10/20/98	Kinstler, et al.			
	A5	5,840,900	11/24/98	Greenwald, et al.			
	A6	5,672,662	9/30/97	Harris, et al.			
	A7	5,824,778	10/20/98	Ishikawa, et al.			
	A8	4,904,584	2/27/90	Shaw			
	A9	5,252,714	10/12/93	Harris, et al.			
	A10	5,510,418	4/23/96	Rhee, et al.			
	A11	4,002,531	1/11/77	Royer			
	A12	4,179,337	12/18/79	Davis, et al.			
	A13	2003/0171285 A1	9/11/03	Finn, et al.			
	A14	2004/0127417 A1	7/1/04	Finn			
	A15	2004/0142870 A1	7/22/04	Finn			
	A16	5,824,784	10/20/98	Kinstler, et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO 99/03887	1/28/99	PCT				
	B2	WO 97/11178	3/27/97	PCT				
	B3	WO 94/20069	9/15/94	WO				
	B4	WO 95/11987	5/4/95	PCT				
	B5	WO 93/00109	1/7/93	PCT				
	B6	WO 03/061577 A2	7/31/03	PCT				
	B7	WO 03/044056 A2	5/30/03	PCT				
	B8	WO 03/049699 A2	6/19/03	PCT				
	B9	WO 02/059179 A2	8/1/02	PCT				
	B10	WO 03/040211 A2	5/15/03	PCT				
	B11	WO 96/08716	3/21/96	PCT				
	B12	WO 98/41562	9/24/98	PCT				
	B13	WO 00/32772	6/8/00	PCT				
	B14	WO 00/42175	7/20/00	PCT				
	B15	JP 11-322916	11/26/99	JP				
	B16	JP 6-233816	8/23/94	JP				

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO.: PC 32152A	APPLICATION NO. 10/771,895
	INVENTOR: Rory F. Finn	
	Filed: February 4, 2004	Group: 1654

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B17	EP 0822199 A2	2/4/98	EP				
	B18	EP 0 458064 A2	11/27/91	EP				
	B19	EP 0 473268 A2	3/4/92	EP				
	B20	EP 0 335423 A2	10/4/89	EP				
	B21	EP 0 372752 B1	5/5/93	EP				
	B22	EP 0 401384 A1	12/12/90	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Allen, D., <i>Growth Suppression by Glucocorticoids</i> , Pediatric Endocrinology, 93-104, 2003
	C2	Allen, D., <i>Growth Hormone Treatment</i> , Pediatric Endocrinology, 87-111, 2003
	C3	Slonim, A., et al., <i>A Preliminary Study of Growth Hormone Therapy for Crohn's Disease</i> , Massachusetts Medical Society, 342(22), 1633-1637, 2000
	C4	Kreitschmann-Andermahr, I., <i>Subarachnoid Hemorrhage as a Cause of Hypopituitarism</i> , Springer Science + Business Media, Inc., 8, 219-225, 2005
	C5	Dusick, A., et al., <i>Growth Failure in the Preterm Infant: Can We Catch Up?</i> , Seminars in Perinatology, 27(4), 302-310, August 2003
	C6	Romano, A., et al., <i>Growth Hormone Treatment in Noonan Syndrome: The National Cooperative Growth Study Experience</i> , The Journal of Pediatrics, 128 (5), 2, S18-S21, 1996
	C7	Vandoorne, F., et al., <i>Functionalization of α-hydrogen-ω-methoxypoly(oxyethylene), 1 A New Method for the Conversion of Hydroxyl End Groups into Aldehyde Groups</i> , Makromol. Chem., Rapid Commun. 10, 271-275, 1989
	C8	Aimaretti, G., et al., <i>Residual Pituitary Function after Brain Injury-Induced Hypopituitarism: A Prospective 12-Month Study</i> , The Journal of Clinical Endocrinology & Metabolism, 90(11) 6085-6092, 2005
	C9	Aimaretti, G., et al., <i>Traumatic Brain Injury and Subarachnoid Haemorrhage are Conditions at High Risk for Hypopituitarism: Screening Study at Three Months after the Brain Injury</i> , Clinical Endocrinology, 61, 320-326, 2004
	C10	Kelly, D., et al., <i>Hypopituitarism Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: A Preliminary Report</i> , J. Neurosurg., 93, 743-752, November 2000
	C11	Kreitschmann-Andermahr, I., et al., <i>Prevalence of Pituitary Deficiency in Patients after Aneurysmal Subarachnoid Hemorrhage</i> , The Journal of Clinical Endocrinology & Metabolism, 89(10) 4986-4992, 2004

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: PC 32152A	APPLICATION NO. 10/771,895
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INVENTOR: Rory F. Finn	
	Filed: February 4, 2004	Group: 1654

C12	Knauf, M., et al., <i>Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers</i> , The Journal of Biological Chemistry, 263 (29), 15064-15070, October 1988
C13	Clark, R., et al., <i>Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol</i> , The Journal of Biological Chemistry, 271(36), 21969-21977, September 1996
C14	Hintz, L., <i>Growth Hormone Treatment of Idiopathic Short Stature</i> , Hormone Research, 46, 208-214, 1996
C15	Wuhl, E., et al., <i>Effects of Growth Hormone in Patients with Chronic Renal Failure: Experience in Children and Adults</i> , Hormone Research, 58, (suppl. 3), 35-38, 2002
C16	Hamed, E., et al., <i>Role of Some Vasoactive Mediators in Patients with Erectile Dysfunction: Their Relationship with Angiotensin-Converting Enzyme and Growth Hormone</i> , International Journal of Impotence Research, 15, 418-425, 2003
C17	Urban, R., <i>Hypopituitarism after Acute Brain Injury</i> , Growth Hormone & IGF Research 16, S25-S29, 2006
C18	Frost, H., <i>Growth Hormone and Osteoporosis: An Overview of Endocrinological and Pharmacological Insights from the Utah Paradigm of Skeletal Physiology</i> , Hormone Research 54 (suppl. 1) 36-43, 2000
C19	Penalver, D., et al., <i>Evaluation of Pituitary Function after a Severe Neurological Event</i> , Endocrinol Nutr., 52(6) 283-290, 2005
C20	Bennett, R., et al., <i>A Randomized, Double-Blind, Placebo-controlled Study of Growth Hormone in the Treatment of Fibromyalgia</i> , The American Journal of Medicine, 104, 227-231, March 1998
C21	Hack, M., et al., <i>The Prognostic Significance of Postnatal Growth in Very Low-birth Weight Infants</i> , Am. J. Obstet. Gynecol., 693-699, July 1982
C22	Chamow, S., et al., <i>Modification of CD4 Immunoconjugates with Monomethoxypoly(ethylene glycol) Aldehyde via Reductive Alkylation</i> , Bioconjugate Chem, 5, 133-140, 1994
C23	Wanke, C., et al., <i>Recombinant Human Growth Hormone Improves the Fat Redistribution Syndrome (lipodystrophy) in Patients with HIV, AIDS</i> , 13(15), 2099-2103, 1999
C24	Olson, K., et al., <i>Preparation and Characterization of PEGylated Human Growth Hormone and Human Growth Hormone Mutants</i> , Polymer Preprints 38, 568-569, 1997
C25	Shearwater Corporation "Catalog 2001" Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages
C26	Nektar Transforming Therapeutics, "Catalog 2003" Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	